Kjell-Morten Myhr

Professor

Department of Clinical Medicine

E-mailKjell-Morten.Myhr@uib.no
Phone+47 55 97 60 31+47 414 47 868
Visitor Address
Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst

5009 Bergen
Postal Address
Postboks 7804

5020 Bergen

Publications

Academic article

Show author(s) (2022). The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis. European Radiology. 3576-3587.
Show author(s) (2022). The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. Neurology: Neuroimmunology and neuroinflammation. 1-10.
Show author(s) (2022). Strong tuberculin response after BCG vaccination is associated with low multiple sclerosis risk: a population-based cohort study. International Journal of Epidemiology. 1637-1644.
Show author(s) (2022). Safety of breast feeding during rituximab treatment in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 4 pages.
Show author(s) (2022). Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry. Journal of Mass Spectrometry and Advances in the Clinical Lab. 53-60.
Show author(s) (2022). Brief international cognitive assessment for MS (BICAMS) and global brain volumes in early stages of MS – A longitudinal correlation study. Multiple Sclerosis and Related Disorders.
Show author(s) (2022). Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. Journal of Neurology. 5901-5909.

Show author(s) (2021). Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study. Neurology. e2789-e2800.
Show author(s) (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. Journal of Neurology, Neurosurgery and Psychiatry. 4 pages.

Show author(s) (2020). Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy. Neurology: Neuroimmunology and neuroinflammation. 1-8.
Show author(s) (2020). High incidence and prevalence of MS in Møre and Romsdal County, Norway, 1950–2018. Neurology: Neuroimmunology and neuroinflammation. 1-10.

Show author(s) (2019). Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis – a pilot trial. Multiple Sclerosis Journal, Experimental, Translational and Clinical. 1-13.

Show author(s) (2018). α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients. Multiple Sclerosis. 987-993.
Show author(s) (2018). Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. European Journal of Neurology. 527-534.

Show author(s) (2017). The prevalence and characteristics of epilepsy in patients with multiple sclerosis in Nordland county, Norway. Seizure. 131-135.
Show author(s) (2017). Survival and cause of death in multiple sclerosis: A 60-year longitudinal population study. Journal of Neurology, Neurosurgery and Psychiatry. 621-625.
Show author(s) (2017). Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study. Multiple Sclerosis. 150-157.
Show author(s) (2017). Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurology: Neuroimmunology and neuroinflammation. 1-8.
Show author(s) (2017). Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study. Multiple Sclerosis. 213-219.
Show author(s) (2017). In-depth cerebrospinal fluid quantitative proteome and deglycoproteome analysis: presenting a comprehensive picture of pathways and processes affected by multiple sclerosis. Journal of Proteome Research. 179-194.
Show author(s) (2017). Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations. NPJ GENOMIC MEDICINE. 12 pages.
Show author(s) (2017). Body size and physical exercise, and the risk of multiple sclerosis. Multiple Sclerosis. 270-278.
Show author(s) (2017). An update on cladribine for relapsing-remitting multiple sclerosis. Expert Opinion on Pharmacotherapy. 1627-1635.
Show author(s) (2017). 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. Neurochemistry International. 262-277.

Show author(s) (2016). WT1 and interferon-β–vitamin D association in MS: a longitudinal study. Acta Neurologica Scandinavica. 309-312.
Show author(s) (2016). Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. European Journal of Neurology. 1064-1070.
Show author(s) (2016). The influence of coping styles on long-term employment in multiple sclerosis: A prospective study. Multiple Sclerosis. 1008-1017.
Show author(s) (2016). The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. Journal of Proteomics & Bioinformatics.
Show author(s) (2016). The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology.
Show author(s) (2016). Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry.
Show author(s) (2016). Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom. Annals of Neurology. 616-624.
Show author(s) (2016). No association of tobacco use and disease activity in multiple sclerosis. Neurology: Neuroimmunology and neuroinflammation. 5 pages.
Show author(s) (2016). Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study. Multiple Sclerosis. 1018-1024.
Show author(s) (2016). Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study. Multiple Sclerosis. 104-111.
Show author(s) (2016). Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. Proteomics. 1154-1165.
Show author(s) (2016). Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis. Mitochondrion (Amsterdam. Print). 32-35.
Show author(s) (2016). Does low socioeconomic status in early life protect against multiple sclerosis? A multinational, case-control study. European Journal of Neurology. 168-174.
Show author(s) (2016). Disease-modifying treatments for multiple sclerosis – a review of approved medications. European Journal of Neurology. 18-27.
Show author(s) (2016). CSF-PR 2.0: an interactive literature guide to quantitative cerebrospinal fluid mass spectrometry data from neurodegenerative disorders. Molecular & Cellular Proteomics. 300-309.
Show author(s) (2016). Allelic imbalance of multiple sclerosis susceptibility genes IKZF3 and IQGAP1 in human peripheral blood. BMC Genetics.
Show author(s) (2016). Alemtuzumab use in clinical practice: recommendations from European multiple sclerosis experts. CNS Drugs. 33-50.
Show author(s) (2016). A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway. Multiple Sclerosis. 100-105.

Show author(s) (2015). Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology. 21-28.
Show author(s) (2015). Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study. Multiple Sclerosis. 1856-1864.
Show author(s) (2015). The EnvIMS study: Design and methodology of an international case-control study of environmental risk factors in multiple sclerosis. Neuroepidemiology. 173-181.
Show author(s) (2015). Reduced duration of breastfeeding is associated with a higher risk of multiple sclerosis in both Italian and Norwegian adult males: the EnvIMS study. Journal of Neurology. 1271-1277.
Show author(s) (2015). Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. Neurochemistry International. 28-40.
Show author(s) (2015). Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort. European Journal of Human Genetics. 688-692.
Show author(s) (2015). Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. European Journal of Neurology. 328-333.
Show author(s) (2015). Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain. 632-643.
Show author(s) (2015). Fingolimod does not enhance cerebellar remyelination in the cuprizone model. Journal of Neuroimmunology. 180-186.
Show author(s) (2015). Cerebrospinal fluid proteomics in multiple sclerosis. Biochimica et Biophysica Acta - Proteins and Proteomics. 746-756.
Show author(s) (2015). Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study. Multiple Sclerosis. 388-395.
Show author(s) (2015). Body mass index influence interferon-beta treatment response in multiple sclerosis. Journal of Neuroimmunology. 92-97.

Show author(s) (2014). Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. Multiple Sclerosis. 1042-1049.
Show author(s) (2014). Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study. Multiple Sclerosis. 669-674.
Show author(s) (2014). Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general. Journal of Neuroimmunology. 174-179.
Show author(s) (2014). Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of clinical and translational neurology. 141-144.
Show author(s) (2014). Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. Journal of Neuroimmunology. 60-65.
Show author(s) (2014). Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study. Multiple Sclerosis. 1074-1080.
Show author(s) (2014). Health related quality of life in patients recently diagnosed with multiple sclerosis. Acta Neurologica Scandinavica. 21-26.
Show author(s) (2014). Employment among patients with multiple sclerosis-A population study. PLOS ONE.
Show author(s) (2014). Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome. PLOS ONE.
Show author(s) (2014). Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 1178-1186.
Show author(s) (2014). Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. PLOS ONE.
Show author(s) (2014). Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. Journal of Neurology, Neurosurgery and Psychiatry. 1109-1115.
Show author(s) (2014). Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Multiple Sclerosis. 1833-1840.

Show author(s) (2013). Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. Journal of Neurology. 1481-1488.
Show author(s) (2013). Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. Multiple Sclerosis. 451-457.
Show author(s) (2013). Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. American Journal of Human Genetics. 854-865.
Show author(s) (2013). Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway. Multiple Sclerosis. 1028-1034.
Show author(s) (2013). Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. PLOS ONE. 9 pages.
Show author(s) (2013). Fat-soluble vitamins as disease modulators in multiple sclerosis. Acta Neurologica Scandinavica. 16-23.
Show author(s) (2013). Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: No. Multiple Sclerosis. 1692-1693.
Show author(s) (2013). Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis. 1074-1083.
Show author(s) (2013). Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. PLOS ONE.
Show author(s) (2013). Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis. 1533-1538.
Show author(s) (2013). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics. 1353-1360.
Show author(s) (2013). Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. PLOS ONE. 5 pages.

Show author(s) (2012). ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomised, double blind, placebo-controlled trial. Archives of Neurology. 1044-1051.
Show author(s) (2012). Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. Acta Neurologica Scandinavica. 63-69.
Show author(s) (2012). Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. Neurology. 267-273.
Show author(s) (2012). The Norwegian Multiple Sclerosis Registry and Biobank. Acta Neurologica Scandinavica. 20-23.
Show author(s) (2012). Modelling and Prediction of 25-Hydroxyvitamin D Levels in Norwegian Relapsing-Remitting Multiple Sclerosis Patients. Neuroepidemiology. 84-93.

Show author(s) (2011). Prevalence and incidence of multiple sclerosis in Oppland County – a cross-sectional population-based study in a landlocked county of Eastern Norway. Acta Neurologica Scandinavica. 250-257.
Show author(s) (2011). Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Multiple Sclerosis. 1074-1078.
Show author(s) (2011). Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 214-219.
Show author(s) (2011). Fatigue in multiple sclerosis: associations with health-related quality of life and physical performance. European Journal of Neurology. 114-120.
Show author(s) (2011). Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus. Genes and Immunity. 191-198.

Show author(s) (2010). Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathology. 720-729.
Show author(s) (2010). Psychometric properties of a Norwegian version of Multiple Sclerosis Impact Scale (MSIS-29). Acta Neurologica Scandinavica. 244-251.
Show author(s) (2010). Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurology. 4 pages.
Show author(s) (2010). Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway. In Vivo. 185-188.
Show author(s) (2010). Benign multiple sclerosis: a need for a consensus. Acta Neurologica Scandinavica. 44-50.
Show author(s) (2010). A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. European Journal of Human Genetics. 502-504.
Show author(s) (2010). A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis. Journal of Proteome Research. 3608-3620.

Show author(s) (2009). Vitamin D treatment in multiple sclerosis. Journal of the Neurological Sciences. 104-108.
Show author(s) (2009). NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurology. 519-529.
Show author(s) (2009). Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway. Multiple Sclerosis. 942-950.
Show author(s) (2009). Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. The Lancet. 1503-1511.
Show author(s) (2009). Depressive symptoms and coping in newly diagnosed patients with multiple sclerosis. Multiple Sclerosis. 638-643.
Show author(s) (2009). Antibodies against interferon-beta in multiple sclerosis. Journal of Neuroimmunology. 148-150.
Show author(s) (2009). A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes and Immunity. 120-124.

Show author(s) (2008). Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Archives of Neurology. 809-811.
Show author(s) (2008). The cuprizone model for demyelination. Acta Neurologica Scandinavica. 72-76.
Show author(s) (2008). The SH2D2A gene and susceptibility to multiple sclerosis. Journal of Neuroimmunology. 152-158.
Show author(s) (2008). Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis. Multiple Sclerosis. 1084-1090.
Show author(s) (2008). Quality of life among young patients with ischaemic stroke compared with patients with multiple sclerosis. Acta Neurologica Scandinavica. 181-185.
Show author(s) (2008). Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. Journal of Neurology. 623-627.
Show author(s) (2008). Environmental risk factors in multiple sclerosis. Acta Neurologica Scandinavica. 34-40.
Show author(s) (2008). Diagnosis and treatment of multiple sclerosis. Acta Neurologica Scandinavica. 12-21.
Show author(s) (2008). Depression and anxiety amongst multiple sclerosis patients. European Journal of Neurology. 239-245.

Show author(s) (2007). Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Multiple Sclerosis. 106-112.
Show author(s) (2007). Pretreatment of mass spectral profiles: Application to proteomic data. Analytical Chemistry. 7014-7026.
Show author(s) (2007). Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. PROTEOMICS - Clinical Applications. 699-711.
Show author(s) (2007). Patient information and coping styles in multiple sclerosis. Multiple Sclerosis. 792-799.
Show author(s) (2007). Low frequency of the disease-associated DRB1*15-DQB1*06 haplotype may contribute to the low prevalence of multiple sclerosis in Sami. Tissue Antigens. 299-304.
Show author(s) (2007). Is smoking an extra hazard in pregnant MS women? Findings from a population-based registry in Norway. European Journal of Neurology. 1113-1117.
Show author(s) (2007). Health-related quality of life in secondary progressive multiple sclerosis. Multiple Sclerosis. 386-392.
Show author(s) (2007). Fc gamma receptor polymorphisms are not associated with autoimmune Addison's disease. Scandinavian Journal of Immunology. 555-558.
Show author(s) (2007). Familial effects on the clinical course of multiple sclerosis. Neurology. 376-383.
Show author(s) (2007). A follow-up study of Nordic multiple sclerosis candidate gene regions. Multiple Sclerosis. 584-589.

Show author(s) (2006). The Norwegian Multiple Sclerosis National Competence Centre and National Multiple Sclerosis Registry - a resource for clinical practice and research. Acta Neurologica Scandinavica. 37-40.
Show author(s) (2006). Planned vaginal births in women with multiple sclerosis: delivery and birth outcome. Acta Neurologica Scandinavica. 51-54.
Show author(s) (2006). Multippel sklerose. Norsk tidsskrift for logopedi. 5-9.
Show author(s) (2006). Multiplexed phosphoprotein analysis in immune cells. Acta Neurologica Scandinavica. 58-60.
Show author(s) (2006). Health-related quality of life among young adults with ischemic stroke on long-term follow-up. Stroke. 1232-2336.
Show author(s) (2006). Fc gamma R and multiple sclerosis: an overview. Acta Neurologica Scandinavica. 61-63.
Show author(s) (2006). Benign multiple sclerosis. Acta Neurologica Scandinavica. 55-57.
Show author(s) (2006). A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. Neurology. 182-186.

Show author(s) (2005). Mild depression in young adults with cerebral infarction at long-term follow-up: A population-based study. European Journal of Neurology. 194-198.
Show author(s) (2005). Fatigue at long-term follow-up in young adults with cerebral infarction. Cerebrovascular Diseases. 245-250.
Show author(s) (2005). Do all young ischemic stroke patients need long-term secondary preventive medication? Neurology. 609-611.

Academic lecture

Show author(s) (2022). Rituximab in the treatment of multiple sclerosis: A pharmacokinetic-pharmacodynamic model.

Show author(s) (2015). Vitamin D og interferon-behandling ved multippel sklerose.
Show author(s) (2015). Evidence of preclinical disease activity a prospective study on cognitive and physical performance prior to first symptom of multiple sclerosis.

Show author(s) (2014). Level of education and multiple sclerosis risk after adjustment for known risk factors: the EnvIMS study.

Show author(s) (2007). Target projection and proper data pre-treatment for the analysis of proteomic profiles.
Show author(s) (2007). Preteatment of Mass Spectral Profiles: Application to proteomic data.
Show author(s) (2007). Analysis of Proteomic Profiles.

Show author(s) (2006). Costs and quality of life in patients with multiple sclerosis in Norway compared to 9 other European countries.

Show author(s) (2000). Reduced quality of life among MS patients with sexual disturbance and bladder dysfunction.
Show author(s) (2000). Quality of life as a predictor for change in disability in multiple sclerosis.
Show author(s) (2000). Livskvalitet hos multippel sklerose pasienter - en utfordring for sykepleien.
Show author(s) (2000). Livskvalitet hos multippel sklerose pasienter.

Show author(s) (1999). The quality of life of multiple sclerosis patients in a treatment trial with recombinant interferon-alfa-2a.
Show author(s) (1999). Lack of agreement between objective disease measures and the Quality of Life in a treatment trial in multiple sclerosis.
Show author(s) (1999). Expanded Disability Status Scale scores and the Quality of Life of Multiple Sclerosis patients. An epidemiological study.

Abstract

Show author(s) (2017). alpha-Linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients. Multiple Sclerosis. 712-712.
Show author(s) (2017). Cancer risk in multiple sclerosis. Multiple Sclerosis. 486-487.

Show author(s) (2013). Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS. Multiple Sclerosis. 33-34.
Show author(s) (2013). Antibodies to Epstein-Barr virus and disease activity in multiple sclerosis. Multiple Sclerosis. 400-400.

Show author(s) (2012). WalkAide - A multidisciplinary model for adjustment and evaluation. Multiple Sclerosis. S30-S30.
Show author(s) (2012). Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology. 18-19.
Show author(s) (2012). Poor sleep in patients with multiple sclerosis. European Journal of Neurology. 706-706.
Show author(s) (2012). Overweight as a risk factor for multiple sclerosis. European Journal of Neurology. 353-353.
Show author(s) (2012). Norwegian quality registry for biological drugs: the NOKBIL project. Scandinavian Journal of Rheumatology. 50-50.
Show author(s) (2012). An age at exposure effect between sun exposure and the risk of MS in Norway and Italy. Multiple Sclerosis. s15-s15.

Show author(s) (2011). VITAMIN D, LIFESTYLE FACTORS AND RISK OF MULTIPLE SCLEROSIS. European Journal of Neurology. 16-16.
Show author(s) (2011). The Risk of Multiple Sclerosis Among Petroleum Workers Exposed to Crude Oil and Other Hydrocarbons. Epidemiology. S60-S60.

Show author(s) (2010). Trend of association to the Glypican 5 gene region to multiple sclerosis. European Journal of Neurology. 221-221.
Show author(s) (2010). The definition of benign multiple sclerosis: a methodical approach. European Journal of Neurology. 494-494.

Show author(s) (2009). Massive up-regulation of immunoglobulin-related genes in the meninges of multiple sclerosis patients without evidence for Epstein-Barr virus infection. Multiple Sclerosis. S5-S5.
Show author(s) (2009). International case control study on risk factors for multiple sclerosis (MS): pilot testing the questionnaire. Multiple Sclerosis. 1403-1403.
Show author(s) (2009). Histopathological characterisation of the cuprizone model for demyelination. Multiple Sclerosis. S177-S177.
Show author(s) (2009). Fatigue in multiple sclerosis is associated with self-perceived health, but less with physical performance. Multiple Sclerosis. S225-S225.

Show author(s) (2008). Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 134-135.
Show author(s) (2008). Gait and balance improved in patients with multiple sclerosis after inpatient physiotherapy. Multiple Sclerosis. S152-S152.
Show author(s) (2008). Fish diet prevents impaired mobility in the murine cuprizone model for multiple sclerosis. Multiple Sclerosis. S90-S91.
Show author(s) (2008). Early diagnosis and biomarker discovery from mass spectral profiles: application to multiple sclerosis. Multiple Sclerosis. S285-S285.
Show author(s) (2008). Biomarker discovery from mass spectral profiles: A combined proteomics and multivariate analysis. European Journal of Pharmaceutical Sciences. S27-S27.
Show author(s) (2008). An international case-control study of risk factors for multiple sclerosis. Multiple Sclerosis. S197-S197.
Show author(s) (2008). Acceptability and cross-cultural feasibility of it self-administered questionnaire on past exposure to putative environmental risk factors for multiple sclerosis. Multiple Sclerosis. S196-S196.

Show author(s) (2007). Smoking habits in pregnant MS women. European Journal of Neurology. 278-278.
Show author(s) (2007). Perinatal factors and later development of multiple sclerosis. Multiple Sclerosis. S91-S92.
Show author(s) (2007). Individualised physiotherapy improved fatigue score in patients with multiple sclerosis. Multiple Sclerosis. S127-S127.
Show author(s) (2007). Increasing prevalence of multiple sclerosis in the elderly in western Norway. Multiple Sclerosis. S96-S96.

Show author(s) (2006). The role of SH2D2A gene polymorphisms in multiple sclerosis. Multiple Sclerosis. S72-S72.
Show author(s) (2006). The role of SH2D2A gene polymorphisms in development of multiple sclerosis. Tissue Antigens. 528-529.
Show author(s) (2006). Pregnancy, delivery and birth outcome in mothers prior to debut of multiple sclerosis. European Journal of Neurology. 28-29.
Show author(s) (2006). Low prevalence of multiple sclerosis in a Sami population is related to low frequency of the disease-associated HLA DR15-DQ6 haplotype. Tissue Antigens. 523-523.
Show author(s) (2006). Low prevalence of multiple sclerosis and the HLA CR15-DQ6 halotype in Sami. Multiple Sclerosis. 71-71.
Show author(s) (2006). Health-related quality of life in secondary progressive multiple sclerosis. European Journal of Neurology. 27-27.

Show author(s) (2005). The CD28/CTLA4/ICOS gene region does not show assosiation in Norwegian multiple sclerosis patients. Genes and Immunity. 1 pages.

Academic literature review

Show author(s) (2022). Relationship between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis. Neurology. E1562-E1573.

Show author(s) (2020). Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Multiple Sclerosis and Related Disorders. 1-10.
Show author(s) (2020). Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. Journal of Neurology. 15 pages.

Show author(s) (2019). Neurofilament light chain as a biomarker in multiple sclerosis. Frontiers in Neurology. 1-6.
Show author(s) (2019). B cell depletion in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy. 261-271.

Show author(s) (2017). Progressive multifocal leukoencephalopathy. Tidsskrift for Den norske legeforening. 10 pages.

Show author(s) (2015). Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. Acta Neurologica Scandinavica. 29-36.
Show author(s) (2015). The Norwegian Multiple Sclerosis Registry and Biobank. Acta Neurologica Scandinavica. 24-28.
Show author(s) (2015). Country break-out session highlights. Neurodegenerative Disease Management. 31-37.

Show author(s) (2014). Multiple sclerosis registries in Europe - Results of a systematic survey. Multiple Sclerosis. 1523-1532.
Show author(s) (2014). Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology. 1210-1216.

Show author(s) (2013). Neuromyelitis optica. Tidsskrift for Den norske legeforening. 2057-2061.
Show author(s) (2013). Clinical assessment and management of sleep disorders in multiple sclerosis: a literature review. Acta Neurologica Scandinavica, Supplementum. 24-30.

Show author(s) (2012). Polyunsaturated fatty acids in multiple sclerosis therapy. Acta Neurologica Scandinavica. 70-75.

Show author(s) (2009). Corticosteroids in the treatment of multiple sclerosis. Acta Neurologica Scandinavica. 73-80.

Show author(s) (2003). New diagnostic criteria in multiple sclerosis. Tidsskrift for Den norske legeforening. 1345-1348.

More information in national current research information system (CRIStin)